The U.S. Food and Drug Administration (FDA) has given fast track designation to Mersana Therapeutics’ XMT-1536 as a possible treatment for women with platinum-resistant high-grade serous ovarian cancer who received up to three prior lines of therapy. The designation also covers those who were treated with four different systemic therapies, regardless of their platinum-disease status. Fast track is meant to facilitate the development and accelerate the review of new medications that aim to treat serious conditions and fill an unmet…
You must be logged in to read/download the full post.
The post XMT-1536 on FDA Fast Track for Platinum-resistant, Advanced Ovarian Cancer appeared first on BioNewsFeeds.